U.S., Oct. 27 -- ClinicalTrials.gov registry received information related to the study (NCT07895160) titled 'Organ Culture for Endocrine Resistant Next Line: A Treatment Selection Study in Metastatic Breast Cancer' on Oct. 13.
Brief Summary: This study evaluates whether testing fresh tumor samples outside the body can help guide treatment selection for patients with hormone receptor-positive, HER2-negative metastatic breast cancer that has progressed during endocrine therapy.
A biopsy sample from each participant will be tested using an ex vivo organ culture (EVOC) platform, which preserves the tumor tissue and allows researchers to assess its response to different anticancer treatments. The results will be used to help select the partici...